Interim test results of the AstraZeneka vaccine
I’ll start from afar. The “launch” of a clinical trial on tens of thousands of people cannot be instantaneous. Recruiting volunteers for such tests is a process stretched out in time (for months) and in space (multiple “strong points”, often in different countries). During this time, unforeseen circumstances may arise that require adjustments in the test report. The final results of Phase 3 clinical trials become known after quite a long time – many months, sometimes years. And when a vaccine is tested against a previously unknown pathogen (which is SARS-CoV-2), all these difficulties are amplified many times over. And time does not wait!
Therefore, protocols for all clinical trials provide an opportunity to summarize and stipulate how and when this should be done.
The Lancet article is the first and so far the only scientific description of such an intermediate analysis (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32661-1/fulltext). It is necessary to clearly understand that this analysis is intermediate, and its results are preliminary. This applies not only to the vaccine, which the article is devoted to (AZD1222 or ChAdOx1 nCoV019), but also to all other coronavirus vaccines, the results of an interim analysis of tests of which, I hope, will be published in the near future.Поділитися цим: